



Adrian Ciurea

Kontakt

Adrian Ciurea

Publikationen (9)

Ciurea A, Götschi A, Bräm R, Bürki K, Exer P, Andor M, Nissen M, Möller B, Hügler T, Rubbert-Roth A, Kyburz D, Distler O, Scherer A, Micheroli R. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry. *RMD Open* 2023; 9

Riek M, Scherer A, Möller B, Ciurea A, Von Mühlengen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller R, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. *Sci Rep* 2023; 13:17776.

Finckh A, Ciurea A, Raptis C, Rubbert-Roth A. Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases. *J Infect Dis* 2023; 228:S13-S23.

Micheroli R, Kissling S, Bürki K, Möller B, Finckh A, Nissen M, Exer P, Bräm R, Kyburz D, Rubbert-Roth A, Andor M, Baraliakos X, de Hooge M, Distler O, Scherer A, Ciurea A. Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry. *Clin Rheumatol* 2023; 42:2377-2385.

Raptis C, Berger C, Ciurea A, Andrey D, Polysopoulos C, Lescuyer P, Maletic T, Riek M, Scherer A, von Loga I, Safford J, Lauper K, Möller B, Vuilleumier N, Finckh A, Rubbert-Roth A. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. *Front Immunol* 2022; 13:1016927.

Ciurea A, Scherer A, Distler O, Kyburz D, Dan D, Müller A, Bräm R, Andor M, Rubbert-Roth A, Möller B, Micheroli R, von Loga I, Bürki K, Papagiannoulis E, Finckh A. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. *Ann Rheum Dis* 2020; 80:238-241.

Alpizar-Rodriguez D, Gabay C, Courvoisier D, Lamacchia C, Mahler M, Roux-Lombard P, Von Mühlengen I, Walker U, Kyburz D, Zufferey P, Ciurea A, Dudler J, Möller B, Müller R, Finckh A. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. *Rheumatology (Oxford)* 2017; 56:1579-1585.

Alpizar-Rodriguez D, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen M, Courvoisier D, Gabay C, Mahler M, Zufferey P, Brulhart L, Müller R, Möller B, Dudler J, Ciurea A, Walker U, Von Mühlengen I, Kyburz D, Finckh A. The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. *Clin Rheumatol* 2017

Ciurea A, Weber U, Boonen A, Dougados M, van der Heijde D, Michel B, Nissen M, Müller R, Weiss B, Tamborrini G, Rufibach K, Stekhoven D, Kissling R, Beyeler B, Dudler J, Bernhard J, Exer P, Scherer A, Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. *Arthritis Rheum* 2013; 65:3096-106.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch